Antibiothérapie empirique lors de neutropénie fébrile
|Published in||Revue médicale suisse. 2008, vol. 4, no. 152, p. 914, 916-919|
|Abstract||Immediate broad-spectrum empirical antibacterial therapy is the key of management in febrile neutropenic patients. These patients can be stratified according to the risk of complications with the clinical MASCC score. Patients at low risk of complications can be efficaciously treated with oral antibiotics (e.g. fluoroquinolone and beta-lactam), provided that compliance and drug absorption are adequate. Early discharge is possible if clinical, logistic, and social criteria are fulfilled. Intravenous antibiotic therapy with broad-spectrum beta-lactam antibiotics in the hospital remains the standard in high-risk patients. The empirical addition of an aminoglycoside and/or a glycopeptide is recommended if the local incidence of infections due to beta-lactam resistant pathogens is high or in critically ill septic patients.|
|Keywords||Anti-Bacterial Agents/ therapeutic use — Fever/ drug therapy — Humans — Neutropenia/ drug therapy — Patient Discharge — Patient Selection|
This document has no fulltext available yet, but you can contact its author by using the form below.
|KRIDEL, R. et al. Antibiothérapie empirique lors de neutropénie fébrile. In: Revue médicale suisse, 2008, vol. 4, n° 152, p. 914, 916-919. https://archive-ouverte.unige.ch/unige:9382|